人 MTBR-Tau243（L243-spanning）抗体对
01AB03508
MTBR-Tau243 targets fragments of the microtubule-binding region of the tau protein, specifically those containing residue 243. In the context of Alzheimer's disease, particular attention is given to the endogenously cleaved form (eMTBR-tau243), which results from specific proteolytic cleavage events at residue 256 and often involves deamidation at residue 255. Unlike N-terminal fragments that may reflect general secretion, these species are believed to be shed directly from insoluble neurofibrillary tangles. Consequently, this biomarker functions as a fluid surrogate for tau aggregate load, showing high specificity for advanced pathology. It demonstrates strong correlations with tau-PET imaging and cognitive decline, making it a critical tool for disease staging and for monitoring the pharmacodynamic response to tau-targeting therapeutic interventions.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- MAPT
- 基因别名
- MAPTL; MTBT1; TAU
- 蛋白别名
- Microtubule-associated protein tau; MTBR-Tau243 (L243-spanning)
- UniProt
- P10636-8
- 物种
- Human
产品详情
- 靶点名称
- MTBR-Tau243 (L243-spanning)
- 蛋白名称
- Microtubule-associated protein tau
- 靶点基因名
- MAPT
- 基因别名
- MAPTL; MTBT1; TAU
- UniProt
- P10636-8
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
MTBR-Tau243 targets fragments of the microtubule-binding region of the tau protein, specifically those containing residue 243. In the context of Alzheimer's disease, particular attention is given to the endogenously cleaved form (eMTBR-tau243), which results from specific proteolytic cleavage events at residue 256 and often involves deamidation at residue 255. Unlike N-terminal fragments that may reflect general secretion, these species are believed to be shed directly from insoluble neurofibrillary tangles. Consequently, this biomarker functions as a fluid surrogate for tau aggregate load, showing high specificity for advanced pathology. It demonstrates strong correlations with tau-PET imaging and cognitive decline, making it a critical tool for disease staging and for monitoring the pharmacodynamic response to tau-targeting therapeutic interventions.